Dostarlimab: An Answer for Rectal Cancer?

Area of Science:

• Oncology
• Immunotherapy
• Gastroenterology

Background:

• Rectal cancer treatment often involves chemotherapy, radiation, and surgery, leading to significant long-term side effects.
• Mismatch repair-deficient (dMMR) rectal cancer is a specific subtype.
• Standard treatments can cause bowel, urinary, sexual dysfunction, infertility, and ostomy.

Purpose of the Study:

• To evaluate the efficacy of the PD-1 inhibitor dostarlimab as a neoadjuvant treatment for locally advanced dMMR rectal cancer.
• To determine if dostarlimab can achieve a clinical complete response without requiring traditional therapies.
• To assess the potential of immunotherapy to spare patients from treatment-related morbidities.

Main Methods:

• A phase II clinical study was conducted.
• Patients with locally advanced dMMR rectal cancer received dostarlimab.
• Clinical complete response was assessed in evaluable patients.

Main Results:

• 100% of evaluable patients achieved a clinical complete response.
• No patients required subsequent chemotherapy, radiation therapy, or surgery.
• The findings suggest a potential to avoid severe adverse events associated with standard treatment.

Conclusions:

• Neoadjuvant dostarlimab demonstrated unprecedented efficacy in locally advanced dMMR rectal cancer.
• Checkpoint blockade with dostarlimab offers a promising organ-sparing alternative to standard treatment.
• This approach may significantly improve quality of life for rectal cancer patients.